BiotechTube
Quercis Pharma

Quercis Pharma

Zug, Switzerland· Est.
quercis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Quercis Pharma is a private, clinical-stage biotech targeting major unmet medical needs in oncology, hematology, immunology, and neurology with a portfolio of investigational small molecule drugs. The company is distinguished by its strong social mission focused on global access and affordability, backed by a leadership team and scientific advisory board with deep industry and academic expertise. While currently pre-revenue, its nomination for a 2025 Galien Award suggests advanced pipeline progress, positioning it as a purpose-driven contender in the biopharma landscape.

OncologyHematologyImmunologyNeurology

Technology Platform

Expert-driven development of small molecule therapies for high-unmet-need conditions, with a core focus on global access and affordability.

Funding History

2
Total raised:$30M
Series B$20M
Series A$10M

Opportunities

The growing global demand for affordable, effective treatments in large therapeutic areas like oncology and immunology presents a massive market.
The company's explicit commitment to equitable access could differentiate it, foster strong relationships with NGOs and governments in emerging markets, and align with increasing payer pressure for cost containment.

Risk Factors

The company faces significant clinical trial risk common to all biotechs, and its social mission-oriented business model may challenge traditional profitability metrics, potentially complicating fundraising or exit strategies.
Execution risk is high in balancing costly drug development with affordable pricing.

Competitive Landscape

Quercis operates in highly competitive fields dominated by large pharmaceutical companies with vast resources. Its differentiation lies not in a novel technology platform but in its patient-access philosophy and expert-guided development. Success will depend on demonstrating superior clinical value and executing its unique access-based commercialization strategy.

More companies in Switzerland →